Healthcare Industry News: Balloon Dilatation Catheter
News Release - June 6, 2006
Boston Scientific Launches New Balloon Catheters Designed to Address Wide Variety of Peripheral Intervention NeedsTechnology Features Powerful Combination of Deliverability and Trackability to Enhance Clinical Versatility
NATICK, Mass., June 6 (HSMN NewsFeed) -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has received FDA clearance to launch its Sterling(TM) Monorail® and Over-the-Wire Balloon Dilatation Catheter in the United States. The balloon catheters are available in a broad range of sizes, offering interventionalists superb clinical versatility. Both balloon catheter platforms are engineered for use in the renal and lower extremity arteries, as well as in dialysis fistula. In addition, the Sterling(TM) Monorail® Catheter received a specific indication for use in the carotid arteries as both a pre- and post-dilatation balloon.
The Sterling Balloon Dilatation Catheter sets a new standard in peripheral angioplasty with its ultra-low profile balloon (4 French), designed to meet the challenges of the peripheral vasculature. "We have incorporated design elements from our industry-leading coronary balloon platform, the Maverick2(TM) Balloon Catheter," said John Pedersen, President of Boston Scientific's Peripheral Interventions Business. "Features such as the laser- formed, tapered tip are designed to facilitate crossing through the most challenging lesions, including tight stenosis and near occlusions."
The Sterling Balloon Dilatation Catheter represents a significant advance in peripheral balloon manufacturing and processing. Its refined profile is complemented by a balanced shaft featuring seamless transitions designed to offer clinicians enhanced trackability and powerful push when faced with traversing challenging anatomy.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.
Source: Boston Scientific
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBoston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX(TM) LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option
Boston Scientific Announces Acquisition of Obsidio, Inc.
Boston Scientific Announces Agreement to Purchase Majority Stake of M.I.Tech Co., Ltd from Synergy Innovation Co., Ltd